La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Agenus a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Agenus..

Agenus (NASDAQ:AGEN) Azioni, Catena delle Opzioni

Agenus

Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).

Agenus Inc

Agent Information Software Inc Com

Agentix Corp

HC Wainwright &amp; Co. analyst Emily Bodnar reiterates Agenus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGEN#NASDAQ">AGEN</a>) from Neutral to Neutral.

News

Reiteration

Analyst Ratings

AGEN

HC Wainwright & Co. Reiterates Neutral on Agenusto Neutral

Baird analyst Colleen Kusy maintains Agenus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGEN#NASDAQ">AGEN</a>) with a Neutral and lowers the price target from $6 to $3.

Price Target

Baird Maintains Neutral on Agenus, Lowers Price Target to $3

Key Operational Highlights:
<ul>
<li>Achieved Q4 2024 operational cash burn of $28.7 million, substantially reducing annualized expenditures.</li>
<li>Initiated further operational cost reductions expected to lower annual burn to approximately $50 million by mid-2025.</li>
<li>Continued aggressive monetization of non-core assets, including manufacturing infrastructure in Emeryville, Berkeley, and Vacaville, CA, to bolster cash position and reduce operating expenses.</li>
</ul>

Biotech

Health Care

General

Agenus Initiated Further Operational Cost Reductions Expected To Lower Annual Burn To Approximately $50M By Mid-2025

Agenus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGEN#NASDAQ">AGEN</a>) reported quarterly losses of $(2.04) per share which beat the analyst consensus estimate of $(2.54) by 19.69 percent. This is a 21.54 percent increase over losses of $(2.60) per share from the same period last year. The company reported quarterly sales of $26.84 million which missed the analyst consensus estimate of $30.27 million by 11.35 percent. This is a 67.98 percent decrease over sales of $83.80 million the same period last year.

Earnings

Agenus Q4 2024 GAAP EPS $(2.04) Beats $(2.54) Estimate, Sales $26.84M Miss $30.27M Estimate

<h3>Companies Reporting Before The Bell</h3>
• Exagen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XGN#NASDAQ">XGN</a>) is projected to report quarterly loss at $0.24 per share on revenue of $13.85 million. 
• Core Molding Technologies (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CMT#AMEX">CMT</a>) is expected to report quarterly earnings at $0.12 per share on revenue of $58.79 million. 
• FuelCell Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FCEL#NASDAQ">FCEL</a>) is expected to report quarterly loss at $1.35 per share on revenue of $33.49 million. 
• BrainsWay (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BWAY#NASDAQ">BWAY</a>) is projected to report quarterly earnings at $0.02 per share on revenue of $10.89 million. 
• Holley (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLLY#NYSE">HLLY</a>) is estimated to report quarterly earnings at $0.02 per share on revenue of $137.60 million. 
• RumbleON (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMBL#NASDAQ">RMBL</a>) is expected to report quarterly loss at $0.23 per share on revenue of $278.42 million. 
• Bioventus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BVS#NASDAQ">BVS</a>) is estimated to report quarterly earnings at $0.08 per share on revenue of $145.16 million. 
• Gauzy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GAUZ#NASDAQ">GAUZ</a>) is estimated to report quarterly loss at $0.21 per share on revenue of $30.33 million. 
• Agenus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGEN#NASDAQ">AGEN</a>) is expected to report quarterly loss at $2.54 per share on revenue of $30.09 million. 
• Kohl's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KSS#NYSE">KSS</a>) is projected to report quarterly earnings at $0.77 per share on revenue of $5.18 billion. 
• First Watch Restaurant Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FWRG#NASDAQ">FWRG</a>) is expected to report quarterly earnings at $0.03 per share on revenue of $263.07 million. 
• United Natural Foods (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNFI#NYSE">UNFI</a>) is likely to report quarterly earnings at $0.16 per share on revenue of $7.96 billion. 
• ECARX Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ECX#NASDAQ">ECX</a>) is likely to report quarterly loss at $0.10 per share on revenue of $240.78 million. 
• Ciena (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CIEN#NYSE">CIEN</a>) is estimated to report quarterly earnings at $0.41 per share on revenue of $1.05 billion. 
• Dick's Sporting Goods (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DKS#NYSE">DKS</a>) is likely to report quarterly earnings at $3.51 per share on revenue of $3.77 billion. 
• Endeavour Silver (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EXK#NYSE">EXK</a>) is projected to report quarterly loss at $0.01 per share on revenue of $47.78 million. 
• Endeavor Group Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EDR#NYSE">EDR</a>) is likely to report quarterly loss at $0.01 per share on revenue of $47.78 million. 
• European Wax Center (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EWCZ#NASDAQ">EWCZ</a>) is projected to report quarterly earnings at $0.06 per share on revenue of $52.17 million. 
• QuantaSing Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QSG#NASDAQ">QSG</a>) is estimated to report quarterly earnings at $0.20 per share on revenue of $98.59 million. 
• Kanzhun (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BZ#NASDAQ">BZ</a>) is likely to report quarterly earnings at $0.21 per share on revenue of $248.09 million. 
• ATRenew (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RERE#NYSE">RERE</a>) is likely to report quarterly earnings at $0.07 per share on revenue of $662.40 million. 
• Legend Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LEGN#NASDAQ">LEGN</a>) is expected to report quarterly loss at $0.33 per share on revenue of $178.93 million. 
• Ferguson Enterprises (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FERG#NYSE">FERG</a>) is expected to report quarterly earnings at $1.60 per share on revenue of $6.76 billion. 
• Achieve Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHV#NASDAQ">ACHV</a>) is expected to report earnings for its fourth quarter. 
• 36KR Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRKR#NASDAQ">KRKR</a>) is expected to report earnings for its Fiscal Year 2024. 
• Syra Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYRA#NASDAQ">SYRA</a>) is projected to report quarterly loss at $0.07 per share on revenue of $2.01 million. 
• Korn Ferry (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KFY#NYSE">KFY</a>) is expected to report quarterly earnings at $1.13 per share on revenue of $650.45 million. 
• Eltek (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELTK#NASDAQ">ELTK</a>) is likely to report quarterly earnings at $0.24 per share on revenue of $13.40 million. 
• Ultralife (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULBI#NASDAQ">ULBI</a>) is expected to report quarterly earnings at $0.15 per share on revenue of $40.00 million. 
• Viking Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VIK#NYSE">VIK</a>) is expected to report quarterly earnings at $0.34 per share on revenue of $1.34 billion. 
• Wheels Up Experience (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UP#NYSE">UP</a>) is estimated to report earnings for its fourth quarter. 
• Global Indemnity Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GBLI#NYSE">GBLI</a>) is expected to report quarterly earnings at $0.78 per share on revenue of $114.00 million. 
• Nuwellis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUWE#NASDAQ">NUWE</a>) is estimated to report quarterly loss at $0.43 per share on revenue of $2.50 million. 
<h3>Companies Reporting After The Bell</h3>
• Champions Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSBR#NASDAQ">CSBR</a>) is projected to report quarterly loss at $0.01 per share on revenue of $12.93 million. 
• Smith Micro Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMSI#NASDAQ">SMSI</a>) is expected to report quarterly loss at $0.11 per share on revenue of $5.13 million. 
• Groupon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRPN#NASDAQ">GRPN</a>) is likely to report quarterly earnings at $0.21 per share on revenue of $127.74 million. 
• SuRo Capital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSSS#NASDAQ">SSSS</a>) is likely to report quarterly loss at $0.21 per share on revenue of $492 thousand. 
• Avino Silver &amp; Gold Mines (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ASM#AMEX">ASM</a>) is projected to report quarterly earnings at $0.01 per share on revenue of $17.20 million. 
• SIGA Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIGA#NASDAQ">SIGA</a>) is likely to report earnings for its fourth quarter. 
• Voyager Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VYGR#NASDAQ">VYGR</a>) is expected to report quarterly loss at $0.35 per share on revenue of $16.58 million. 
• Zynex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZYXI#NASDAQ">ZYXI</a>) is projected to report quarterly earnings at $0.09 per share on revenue of $53.65 million. 
• Verrica Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRCA#NASDAQ">VRCA</a>) is estimated to report quarterly loss at $0.24 per share on revenue of $1.30 million. 
• Superior Gr of Cos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGC#NASDAQ">SGC</a>) is expected to report quarterly earnings at $0.17 per share on revenue of $146.54 million. 
• E W Scripps (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSP#NASDAQ">SSP</a>) is expected to report quarterly earnings at $0.99 per share on revenue of $716.06 million. 
• Cadre Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CDRE#NYSE">CDRE</a>) is expected to report quarterly earnings at $0.51 per share on revenue of $171.77 million. 
• Zevra Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZVRA#NASDAQ">ZVRA</a>) is projected to report quarterly loss at $0.40 per share on revenue of $8.93 million. 
• Pursuit Attractions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRSU#NYSE">PRSU</a>) is estimated to report earnings for its fourth quarter. 
• Grove Collaborative Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GROV#NYSE">GROV</a>) is projected to report quarterly loss at $0.15 per share on revenue of $48.79 million. 
• Synchronoss Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNCR#NASDAQ">SNCR</a>) is projected to report quarterly earnings at $0.09 per share on revenue of $43.76 million. 
• Natures Sunshine Products (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NATR#NASDAQ">NATR</a>) is expected to report quarterly earnings at $0.20 per share on revenue of $109.46 million. 
• Finance of America (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FOA#NYSE">FOA</a>) is likely to report quarterly earnings at $0.46 per share on revenue of $80.61 million. 
• Concrete Pumping Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBCP#NASDAQ">BBCP</a>) is projected to report quarterly earnings at $0.03 per share on revenue of $89.86 million. 
• loanDepot (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LDI#NYSE">LDI</a>) is likely to report quarterly loss at $0.01 per share on revenue of $310.08 million. 
• CuriosityStream (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CURI#NASDAQ">CURI</a>) is estimated to report quarterly loss at $0.02 per share on revenue of $13.10 million. 
• Stitch Fix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SFIX#NASDAQ">SFIX</a>) is projected to report quarterly loss at $0.11 per share on revenue of $297.27 million. 
• Eastern (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EML#NASDAQ">EML</a>) is likely to report earnings for its fourth quarter. 
• Allbirds (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIRD#NASDAQ">BIRD</a>) is estimated to report quarterly loss at $3.45 per share on revenue of $55.86 million. 
• Westrock Coffee (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WEST#NASDAQ">WEST</a>) is expected to report quarterly loss at $0.12 per share on revenue of $228.75 million. 
• Casey's General Stores (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CASY#NASDAQ">CASY</a>) is likely to report quarterly earnings at $2.59 per share on revenue of $3.78 billion. 
• Oil-Dri Corp of America (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ODC#NYSE">ODC</a>) is projected to report earnings for its second quarter. 
• Vitesse Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTS#NYSE">VTS</a>) is estimated to report quarterly earnings at $0.24 per share on revenue of $65.19 million. 
• Bowman Consulting Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BWMN#NASDAQ">BWMN</a>) is estimated to report quarterly earnings at $0.27 per share on revenue of $110.71 million. 
• MaxCyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MXCT#NASDAQ">MXCT</a>) is estimated to report quarterly loss at $0.13 per share on revenue of $7.67 million. 
• Heritage Insurance Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HRTG#NYSE">HRTG</a>) is likely to report quarterly earnings at $0.58 per share on revenue of $208.37 million. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ACHV

BBCP

BIRD

BWAY

BWMN

CASY

CDRE

CIEN

CSBR

CURI

ELTK

EWCZ

FCEL

FERG

FWRG

GAUZ

GBLI

GROV

GRPN

HLLY

HRTG

KRKR

LEGN

MXCT

NATR

NUWE

PRSU

RERE

RMBL

SFIX

SIGA

SMSI

SNCR

SSSS

SYRA

ULBI

UNFI

VRCA

VYGR

WEST

ZVRA

ZYXI

Earnings Scheduled For March 11, 2025

Events

Agenus Reports Impact Of Immuno-Oncology Data

Incyte previously terminated the OX40 program (effective October 2023) and the GITR and an undisclosed program (effective May 2024). In July 2024, Incyte announced that it would discontinue development of its LAG-3 and TIM-3 programs.&nbsp;
With this termination, Agenus will regain full control of these assets and will evaluate future opportunities for their advancement, including internal development and potential new partnerships.
 &nbsp;
&nbsp;
 &nbsp;

Agenus Says Received Formal Notice On February 4 From Incyte Electing To Terminate Agreement Effective February 4, 2026, In Line With Strategic Portfolio Reprioritization; Upon Termination, All Rights To LAG-3 And TIM-3 Revert To Agenus

Agenus Publishes Data Of Study Of Botensilimab In Combination With Balstilimab In Patients With Relapsed/Refractory Metastatic Sarcomas In Journal of Clinical Oncology

Agenus Announced Five Presentations Featuring Botensilimab (Bot, An Fc-enhanced Anti-CTLA-4 Antibody) Plus Balstilimab (Bal, An Anti-PD-1 Antibody) At The Upcoming American Society Of Clinical Oncology Gastrointestinal Cancers Symposium

This initiative follows the successful closing of a $22 million mortgage secured by key real estate assets, providing the company with enhanced operational flexibility during this pivotal period.&nbsp;
Key Measures Include:
<ul>
<li>Focusing on BOT/BAL: Agenus will concentrate its resources on its lead botensilimab/balstilimab (BOT/BAL) program, which has demonstrated robust clinical activity in microsatellite stable colorectal cancer (MSS CRC), non-small cell lung cancer (NSCLC), pancreatic cancer, sarcoma, and other difficult-to-treat cancers.</li>
<li>Reducing Costs: The company will implement significant cost-cutting measures, including staff reductions and operational adjustments, targeting a 60% reduction in annual expenditures and a cash burn of $100 million for FY 2025.</li>
<li>Optimizing Expert Manufacturing Capabilities: Agenus plans to transition its biologics CMC capabilities to a fee-for-service model, unlocking new revenue opportunities. This initiative is intended to be supported by external funding.</li>
</ul>

Agenus Announced Further Details Of Its Strategic Realignment, Reductions Are Designed To Reduce Cash Burn To $100M In FY 2025

HC Wainwright &amp; Co. analyst Emily Bodnar reiterates Agenus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGEN#NASDAQ">AGEN</a>) with a Neutral and maintains $7 price target.

HC Wainwright & Co. Reiterates Neutral on Agenus, Maintains $7 Price Target

Agenus Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGEN#NASDAQ">AGEN</a>) shares are trading higher<a target="_blank" href="https://www.benzinga.com/premarket" rel="noreferrer noopener"> in the morning session on Wednesday.</a>
The company has secured a $22 million non-amortizing mortgage, backed by its Berkeley-based Biologics CMC facility and its 66-acre <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b42212789/agenus-secures-22-million-mortgage-and-announces-strategic-operational-realignment" rel="noreferrer noopener">biomanufacturing-zoned property in Vacaville, California.</a>
The deal, facilitated by L&amp;L Capital, provides $20 million in net proceeds after closing costs and interest reserve, boosting Agenus&#8217; cash position ahead of anticipated further cash infusions in the coming months.
The mortgage is structured with a two-year term, carrying interest rates of 12% for the first year and 13% for the second, with payments split 50% in cash and 50% in common stock.
In parallel, Agenus is executing a Strategic Operational Realignment Plan to focus its efforts on its promising botensilimab/balstilimab (BOT/BAL) in MSS colorectal cancer (CRC).
Also Read: <a target="_blank" href="https://www.benzinga.com/24/11/42210528/us-stock-futures-signal-a-muted-open-smallcaps-may-advance-analyst-flags-cross-asset-volatility" rel="noreferrer noopener">Major US Stock Futures Slide, Small-Caps Buck Trend: Market Strategist Flags This As The &#8216;Stronger Times Of The Year For Stocks&#8217;</a>
The plan includes a projected 60% reduction in annual external expenditures and a transition of the company&#8217;s CMC capabilities into a fee-for-service biologics manufacturing business. These measures, along with additional planned optimizations, are expected to reduce Agenus&#8217; FY 2025 cash burn to approximately $100 million.
BOT/BAL has demonstrated strong clinical activity in MSS CRC and other cancers resistant to existing therapies. Agenus is preparing for late-stage development and regulatory strategies, targeting both regional and global registration pathways. The company&#8217;s strategic realignment aims to revolutionize cancer treatment while positioning Agenus for long-term growth and patient impact.
Price Action: AGEN shares are trading higher by 16.3% to $3.93 at last check Wednesday.
Read next:&nbsp;
<ul>
<li><a href="http://jd%20vance's%20investment%20playbook%20has%20bitcoin%20and%20etfs:%20Here's%20What%20Else%20The%20VP-Elect%20Is%20Betting%20On/" target="_blank" rel="noreferrer noopener">JD Vance's Investment Playbook Has Bitcoin And ETFs: Here's What Else The VP-Elect Is Betting On</a></li>
</ul>
Image via Unsplash.

Equities

Markets

Movers

Agenus Gets $22M Mortgage, Plans Strategic Realignment To Focus On Colorectal Cancer Drug Development

HC Wainwright &amp; Co. analyst Emily Bodnar maintains Agenus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGEN#NASDAQ">AGEN</a>) with a Neutral and lowers the price target from $8 to $7.

HC Wainwright & Co. Maintains Neutral on Agenus, Lowers Price Target to $7

Agenus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGEN#NASDAQ">AGEN</a>) reported quarterly losses of $(3.08) per share which missed the analyst consensus estimate of $(2.33) by 32.19 percent. This is a 6.38 percent increase over losses of $(3.29) per share from the same period last year. The company reported quarterly sales of $25.110 million which missed the analyst consensus estimate of $33.476 million by 24.99 percent. This is a 3.27 percent increase over sales of $24.314 million the same period last year.

Earnings Misses

Agenus Q3 2024 GAAP EPS $(3.08) Misses $(2.33) Estimate, Sales $25.110M Miss $33.476M Estimate. Cash and Equivalents of $44.8M

ABOS

ABSI

ACNT

ACTG

AENT

AIOT

AIRG

ALIT

ALTG

AMBC

AMPS

AMTX

APEI

AREB

ARIS

ARMN

ATRA

AUTL

Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

AVDL

AXSM

AZTA

BHIL

BLDE

BLFS

BLTE

The Beachbody Company, Inc. Class A Common Stock

BODI

BRTX

BTMD

BTTR

BXSL

BZFD

CAMT

CART

CATX

CAVA

CBAT

CBLL

CCLD

CGEN

CHGG

CHMI

CLSD

CNNE

CRNX

CRON

CRVS

CRWS

CVAC

CXAI

DAVA

DAVE

DRCT

DYAI

EARN

EGAN

ELMD

ETON

EVCM

EVGO

EYEN

FENG

FGEN

FIHL

FLNG

FOUR

FTCI

GENI

GENK

GMGI

GOVX

GRAL

GRDN

GRVY

Earnings Scheduled For November 12, 2024

Agenus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGEN#NASDAQ">AGEN</a>) will release its quarterly earnings report on Tuesday, 2024-11-12. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Agenus to report an earnings per share (EPS) of $-2.33.
The market awaits Agenus's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Earnings History Snapshot</h3>
In the previous earnings release, the company missed EPS by $1.08, leading to a 3.6% drop in the share price the following trading session.
Here's a look at Agenus's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-1.44</td>
<td>-2.83</td>
<td>-1</td>
<td>-3.8</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-2.52</td>
<td>-3.04</td>
<td>-2.6</td>
<td>-3.2</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-4.0%</td>
<td>-4.0%</td>
<td>-10.0%</td>
<td>2.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1731344491_0.png" alt="eps graph" />
<h3>Agenus Share Price Analysis</h3>
Shares of Agenus were trading at $3.905 as of November 08. Over the last 52-week period, shares are down 73.39%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<a href="https://www.benzinga.com/quote/AGEN/earnings">To track all earnings releases for Agenus visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insights Ahead: Agenus's Quarterly Earnings

Novel Candidates Show Promise in Turning Cold and Refractory Tumors into Responsive Targets
Agenus Inc. ("Agenus") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGEN#NASDAQ">AGEN</a>), a leader in developing novel immunological agents to treat various cancers, today announced the presentation of new data on two of its promising investigational immunotherapy candidates, botensilimab and AGEN1721, at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting in Houston, Texas. The data, showcasing potential breakthroughs in treating immune-resistant tumors, will be presented by Dhan Chand, Ph.D., Vice President of Research at Agenus.

Agenus To Present Data On Botensilimab And AGEN1721 At SITC 2024; Novel Candidates Show Promise In Turning Cold And Refractory Tumors Into Responsive Targets

Press Releases

Agenus Presents Data at ASCO GI Demonstrating Impact of BOT/BAL in Colorectal Cancer Across Neoadjuvant and Advanced Disease

Agenus Announces Publication in the Journal of Clinical Oncology Highlighting Data from Botensilimab Plus Balstilimab in Relapsed/Refractory Metastatic Sarcomas

Agenus' BOT/BAL Selected for Two Presentations at Upcoming AACR IO Annual Meeting

Agenus Presents New Botensilimab/Balstilimab Data in Gastric Cancer at AACR IO Annual Meeting

Agenus to Provide Corporate Update and Fourth Quarter & Full Year 2024 Financial Report

Agenus to Participate in B. Riley Securities Precision Oncology & Radiopharma Investor Conference

Agenus Reports Impact of Key Immuno-Oncology Data Presented at Leading Medical Conferences and Peer-Reviewed Publications

Agenus Reports Q4 and Year-End 2024 Results; Strategic Operational Improvements and Significant Cost Reductions Enhance Sustainability of Promising BOT/BAL Program

Agenus Unveils Colorectal Cancer Survey Findings, Highlighting the Urgent Need for Treatment Innovation

Comments

Agenus

Agenus (AGEN) Opzioni

Agenus (NASDAQ:AGEN) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO